Orbimed Advisors LLC Takes Position in CeriBell (NASDAQ:CBLL)

Orbimed Advisors LLC bought a new position in CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 112,500 shares of the company's stock, valued at approximately $2,912,000. Orbimed Advisors LLC owned 0.31% of CeriBell at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Legal & General Group Plc bought a new stake in CeriBell in the fourth quarter worth about $32,000. Summit Investment Advisors Inc. bought a new stake in shares of CeriBell in the 4th quarter worth approximately $33,000. Tower Research Capital LLC TRC acquired a new stake in CeriBell during the fourth quarter valued at approximately $37,000. BNP Paribas Financial Markets bought a new stake in CeriBell during the fourth quarter worth approximately $43,000. Finally, PNC Financial Services Group Inc. acquired a new position in CeriBell in the fourth quarter worth approximately $47,000.

CeriBell Trading Up 7.5%

NASDAQ:CBLL opened at $17.16 on Tuesday. CeriBell has a 1-year low of $10.01 and a 1-year high of $32.75. The company's fifty day simple moving average is $17.93.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. The company had revenue of $20.49 million for the quarter, compared to analyst estimates of $19.30 million. Equities research analysts predict that CeriBell will post -2.46 EPS for the current year.

Insider Activity

In related news, CEO Xingjuan Chao sold 15,628 shares of the stock in a transaction on Wednesday, April 23rd. The stock was sold at an average price of $15.11, for a total transaction of $236,139.08. Following the completion of the sale, the chief executive officer now directly owns 727,151 shares in the company, valued at approximately $10,987,251.61. This trade represents a 2.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 24,700 shares of company stock worth $372,434 in the last ninety days.

Analyst Upgrades and Downgrades

CBLL has been the subject of a number of recent research reports. LADENBURG THALM/SH SH started coverage on CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 price objective for the company. Canaccord Genuity Group reaffirmed a "buy" rating and set a $33.00 target price on shares of CeriBell in a report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $32.50.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.